Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 4,31 € (+92,41 %). La mediana es de 4,31 € (+92,41 %).
| Comprar |
6 |
| Mantener |
3 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Sensus Healthcare: shareholders re-elect directors and ratify auditor
At Sensus Healthcare’s annual meeting, Eric Sachetta and Michael J. Sardano were re-elected as Class II directors for three-year terms. Shareholders also voted, in a non-binding advisory vote, to approve executive compensation for 2025 and ratified Carr, Riggs & Ingram as the independent auditor for fiscal year 2026. Sensus reported weak Q1 results with EPS of -$0.16 and revenue of $3.4 million, while the stock is trading near its 52-week low. » Más en de.investing.com
Sensus Healthcare misses Q1 forecasts after sharp revenue decline
Sensus Healthcare reported Q1 2026 EPS of -$0.16 and revenue of $3.4 million, both below analyst expectations. Revenue fell 59% year over year, weighed down by missed sales to its largest customer and a shift to new business models. Adjusted revenue growth on a comparable basis was +26%. Management sees potential in new specific CPT codes and the Sensus Link software platform to improve reimbursement and drive future revenue growth. » Más en de.investing.com
Acquisition leads to change of auditor at Sensus Healthcare
Sensus Healthcare dismissed Berkowitz Pollack Brant Advisors + CPAs (BPB) and appointed Carr, Riggs & Ingram (CRI) as its new independent auditor after CRI acquired certain assets of BPB’s capital markets business (effective Jan. 1, 2026). BPB’s audit report for the fiscal year ended Dec. 31, 2024, contained no disclaimers, modifications or disagreements with Sensus. The company also reported that a previously disclosed material IT-related control weakness had been remediated as of Dec. 31, 2024. In addition, Sensus reported revenue that exceeded expectations in the third quarter of 2025 and several board and management personnel changes, including the appointment of Larry Biscotti to the board of directors and the promotion of Michael Sardano to chief commercial officer. » Más en de.investing.com
Sensus Healthcare adds Eric Sachetta to board of directors
Sensus Healthcare has appointed Eric Sachetta to its board of directors; he replaces the late longtime member Bill McCall. Sachetta comes from Sachetta, LLC and brings experience in financial advisory, leadership and client service, as well as several professional qualifications. The micro‑cap company (about $69m) has recently seen a share-price rise but is struggling with profitability; for Q3/2025 Sensus beat revenue and earnings forecasts (revenue $6.9m, loss per share $0.06). » Más en de.investing.com
Sensus Healthcare beats Q3 revenue forecast, stock rises in after-hours trading
Sensus Healthcare reported Q3 2025 revenue of $6.9 million, topping the forecast of $6.25 million. Earnings per share were -$0.06 versus an expected -$0.08, and the net loss was $0.9 million. Gross margin fell to 39.1%, while the cash position rose to $24.5 million. Management points to new reimbursement codes and international expansion (focus on Japan) as growth drivers; the stock increased 5.15% in after-hours trading. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 2,01 M | 67,67 % |
| Beneficio bruto | 673,81 mil | 72,64 % |
| Beneficio neto | -7,67 M | 771,32 % |
| EBITDA | -2,66 M | 95,53 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 48,61 M € |
Número de acciones | 16,46 M |
Máximo/mínimo de 52 semanas | 4,98 € - 2,41 € |
| Dividendos | No |
Beta | 1,19 |
Ratio P/E | -3,47 |
Ratio PEG | 0,03 |
Ratio P/B | 1,45 |
Ratio P/S | 3,06 |
Perfil de la empresa
Sensus Healthcare, Inc., una empresa de dispositivos médicos, fabrica y vende dispositivos de radioterapia a proveedores de atención médica en todo el mundo. La empresa utiliza la radioterapia superficial (SRT, por sus siglas en inglés), una tecnología de rayos X de baja energía, en su cartera de dispositivos de tratamiento. Ofrece el SRT-100, un sistema de radioterapia superficial de baja energía con rayos X de fotones que proporciona a los pacientes una alternativa a la cirugía para tratar cánceres de piel distintos del melanoma, incluidos los carcinomas basocelulares y los carcinomas de células escamosas, así como otras afecciones cutáneas, como los queloides; y el SRT-100 Vision, que ofrece al usuario una aplicación de planificación de tratamiento adaptada a la SRT que integra el módulo de ecografía de alta frecuencia incorporado, el análisis volumétrico de tumores, la planificación de los márgenes del haz y los parámetros de dosimetría. La empresa también ofrece el SRT-100 Plus; el programa de servicio Sentinel, que brinda a sus clientes protección para sus sistemas; y servicios de alquiler de láser para consultorios. Además, vende reemplazos desechables de blindaje de plomo y artículos desechables de seguridad contra la radiación, como delantales y protectores oculares, película para sondas de ultrasonido y puntas aplicadoras desechables para tratar lesiones de distintos tamaños y diversas zonas del cuerpo. Sensus Healthcare, Inc. se constituyó en 2010 y tiene su sede en Boca Raton, Florida.
| Nombre | SENSUS HEALTHCARE DL-,01 Aktie |
| CEO | Joseph C. Sardano |
| Sede | Boca Raton,
fl Estados Unidos |
| Sitio web | |
| Sector | Consumo discrecional |
| Industria | Bienes duraderos del hogar |
| Salida a bolsa | 26/07/2016 |
| Empleados | 60 |
Deep Dive
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | SRTS |
Frankfurt | 5TX.F |
Düsseldorf | 5TX.DU |
München | 5TX.MU |
